KR102456032B1 - 눈에서 지속적 약물 방출을 달성하기 위한 방법 및 생체적합성 조성물 - Google Patents

눈에서 지속적 약물 방출을 달성하기 위한 방법 및 생체적합성 조성물 Download PDF

Info

Publication number
KR102456032B1
KR102456032B1 KR1020177006261A KR20177006261A KR102456032B1 KR 102456032 B1 KR102456032 B1 KR 102456032B1 KR 1020177006261 A KR1020177006261 A KR 1020177006261A KR 20177006261 A KR20177006261 A KR 20177006261A KR 102456032 B1 KR102456032 B1 KR 102456032B1
Authority
KR
South Korea
Prior art keywords
drug
wafer
nanostructured
nanomesh
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177006261A
Other languages
English (en)
Korean (ko)
Other versions
KR20170052582A (ko
Inventor
시카 피. 바먼
몰리 리우
커식 바먼
케빈 엘. 워드
브렌든 해켓
Original Assignee
인티그럴 바이오시스템스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인티그럴 바이오시스템스 엘엘씨 filed Critical 인티그럴 바이오시스템스 엘엘씨
Publication of KR20170052582A publication Critical patent/KR20170052582A/ko
Application granted granted Critical
Publication of KR102456032B1 publication Critical patent/KR102456032B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
KR1020177006261A 2014-09-06 2015-09-08 눈에서 지속적 약물 방출을 달성하기 위한 방법 및 생체적합성 조성물 Active KR102456032B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046918P 2014-09-06 2014-09-06
US62/046,918 2014-09-06
PCT/US2015/048795 WO2016037169A1 (en) 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye

Publications (2)

Publication Number Publication Date
KR20170052582A KR20170052582A (ko) 2017-05-12
KR102456032B1 true KR102456032B1 (ko) 2022-10-18

Family

ID=55440434

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006261A Active KR102456032B1 (ko) 2014-09-06 2015-09-08 눈에서 지속적 약물 방출을 달성하기 위한 방법 및 생체적합성 조성물

Country Status (12)

Country Link
US (2) US9931306B2 (enExample)
EP (1) EP3188688B1 (enExample)
JP (2) JP7026507B2 (enExample)
KR (1) KR102456032B1 (enExample)
CN (2) CN109481447A (enExample)
AU (2) AU2015311637B2 (enExample)
CA (1) CA2960213C (enExample)
ES (1) ES2900025T3 (enExample)
MY (1) MY178327A (enExample)
SG (1) SG11201701714RA (enExample)
WO (1) WO2016037169A1 (enExample)
ZA (2) ZA201701467B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7026507B2 (ja) * 2014-09-06 2022-02-28 インテグラル バイオシステムズ エルエルシー 眼において薬物徐放を達成する方法及び生体適合性組成物
WO2017062770A1 (en) 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
WO2018064648A1 (en) * 2016-09-30 2018-04-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
US10492945B2 (en) * 2017-05-22 2019-12-03 California Institute Of Technology Small molecule transport device with anti-condensation filler for drug delivery or waste removal
US20200206137A1 (en) * 2017-07-17 2020-07-02 Wolfcreek Biotech Pte Ltd Microparticle formulations for delivery of active agents
CN117064634A (zh) 2018-03-01 2023-11-17 巴伊兰大学 用于修正眼部状态的系统、方法及材料组成物
CA3101088A1 (en) * 2018-06-05 2019-12-12 Corneat Vision Ltd. A synthetic ophthalmic graft patch
CN109853054A (zh) * 2019-02-27 2019-06-07 上海交通大学医学院附属第九人民医院 一种同轴静电纺丝三维打印生物支架的装置及搭建方法
EP3701974B1 (en) * 2019-02-28 2024-08-28 Agency for Science, Technology and Research A material suitable for use as a vitreous substitute and related methods
MX2021010599A (es) 2019-03-05 2021-12-10 Aerie Pharmaceuticals Inc Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.
AU2020251710A1 (en) * 2019-04-02 2021-11-25 Cytomatrix Limited A composition for the delivery of biologically active agents and uses thereof
TWI826685B (zh) 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
BR112022007332A2 (pt) 2019-10-24 2022-07-05 E Labombard Denis Dispositivo ocular, métodos, composição, caixa para conter e dispensar um dispositivo ocular e kit
CN114760987A (zh) * 2019-12-10 2022-07-15 爱尔康公司 具有可生物降解聚合物的可溶解性聚合物眼睛插入物
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
KR102467288B1 (ko) * 2020-06-09 2022-11-17 동국대학교 산학협력단 결막 접촉용 약물 전달기
EP3928805A1 (en) * 2020-06-26 2021-12-29 Royal College of Surgeons in Ireland A device for use in the delivery of an active agent
EP4247367A4 (en) * 2020-11-23 2024-10-16 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
WO2022250977A1 (en) * 2021-05-26 2022-12-01 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN114869862A (zh) * 2022-04-24 2022-08-09 温州医科大学附属眼视光医院 一种带引流功能的青光眼手术缓释抗瘢痕膜及制备方法
WO2025050106A1 (en) * 2023-08-31 2025-03-06 University Of Tennessee Research Foundation Sustained release ocular implants
WO2025255203A1 (en) * 2024-06-06 2025-12-11 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269391A1 (en) 2008-04-29 2009-10-29 Ocugenics, L.L.C. Drug Delivery System And Methods Of Use
US20100331975A1 (en) 2009-06-25 2010-12-30 Optonol Ltd. Fiber matrix for maintaining space in soft tissues
JP2013511527A (ja) 2009-11-17 2013-04-04 アーセナル メディカル， インコーポレイテッド 薬物添加繊維

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5177168A (en) * 1989-10-17 1993-01-05 Polymer Technology Corp. Polymeric compositions useful in oxygen permeable contact lenses
DE69520044T2 (de) 1994-10-12 2001-06-13 Focal, Inc. Zielgerichte verabreichung mittels biologisch abbaubarer polymere
US8273366B2 (en) 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
WO2006126182A2 (en) 2005-05-24 2006-11-30 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens and methods of use
BRPI0622041B8 (pt) * 2006-09-28 2021-06-22 Essity Hygiene & Health Ab artigo absorvente e método de fabricação para fabricar um artigo absorvente.
CN101687031B (zh) * 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
EP2091481A2 (en) * 2006-12-18 2009-08-26 Alcon Research, Ltd. Devices and methods for ophthalmic drug delivery
US8974814B2 (en) * 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
US8361492B2 (en) * 2008-04-29 2013-01-29 Ocugenics, LLC Drug delivery system and methods of use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
CN102395401B (zh) 2009-02-12 2015-08-19 因赛普特有限责任公司 经由水凝胶塞的药物递送
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
KR20180117211A (ko) 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US20110229551A1 (en) * 2010-03-17 2011-09-22 Notus Laboratories, Inc. Drug delivery compositions and methods using nanofiber webs
US9028860B2 (en) * 2010-04-28 2015-05-12 Poly-Med, Inc. Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery
WO2012114138A1 (fr) * 2011-02-21 2012-08-30 Cerebel-Invest Sa Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active
US8715713B2 (en) 2011-04-29 2014-05-06 Allergan, Inc. Solvent cast film sustained release latanoprost implant
KR102192603B1 (ko) 2011-09-14 2020-12-17 포사이트 비젼5, 인크. 안내 삽입물 장치 및 방법
CN203089455U (zh) * 2013-02-01 2013-07-31 浙江大学医学院附属第二医院 襻上镶嵌有药物缓释微囊的人工晶状体
JP7026507B2 (ja) * 2014-09-06 2022-02-28 インテグラル バイオシステムズ エルエルシー 眼において薬物徐放を達成する方法及び生体適合性組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269391A1 (en) 2008-04-29 2009-10-29 Ocugenics, L.L.C. Drug Delivery System And Methods Of Use
US20100331975A1 (en) 2009-06-25 2010-12-30 Optonol Ltd. Fiber matrix for maintaining space in soft tissues
JP2012531274A (ja) 2009-06-25 2012-12-10 オプトノール リミティド 軟組織において空間を維持する繊維マトリックス
JP2013511527A (ja) 2009-11-17 2013-04-04 アーセナル メディカル， インコーポレイテッド 薬物添加繊維

Also Published As

Publication number Publication date
US10328033B2 (en) 2019-06-25
AU2019250153B2 (en) 2021-02-04
CA2960213A1 (en) 2016-03-10
JP7026507B2 (ja) 2022-02-28
US20170296483A1 (en) 2017-10-19
MY178327A (en) 2020-10-08
AU2015311637B2 (en) 2019-07-18
EP3188688B1 (en) 2021-11-03
JP2017526655A (ja) 2017-09-14
CA2960213C (en) 2023-03-28
SG11201701714RA (en) 2017-04-27
NZ729467A (en) 2024-04-26
JP2022001582A (ja) 2022-01-06
EP3188688A4 (en) 2018-07-25
CN106604695B (zh) 2018-10-23
EP3188688A1 (en) 2017-07-12
CN109481447A (zh) 2019-03-19
ZA201705792B (en) 2018-12-19
AU2019250153A1 (en) 2019-10-31
AU2015311637A1 (en) 2017-03-23
ES2900025T3 (es) 2022-03-15
US9931306B2 (en) 2018-04-03
ZA201701467B (en) 2018-04-25
KR20170052582A (ko) 2017-05-12
CN106604695A (zh) 2017-04-26
WO2016037169A1 (en) 2016-03-10
US20180280313A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
AU2019250153B2 (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
Allyn et al. Considerations for polymers used in ocular drug delivery
CN111743878B (zh) 用于眼科应用和/或其它应用的组合物以及方法
Chennamaneni et al. Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation
WO2008157614A2 (en) Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
CN111700880A (zh) 显示提高的粘膜转移的药物纳米粒子
US20240197740A1 (en) Methotrexate treatment methods
Jani et al. Ocular Drug Delivery Systems
HK40003833A (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
HK1235660B (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
Herrero-Vanrell et al. Ocular pharmacokinetic drug, bioavailability and intraocular drug delivery systems
Tawfik Dual Drug-Loaded Electrospun Nanofibres for the Treatment of Corneal Diseases
Bhaskar et al. Eye Drops to smart gels: The future of ocular drug delivery.
JP2015074641A (ja) 眼内薬物送達デバイスおよび付随する方法
HK40039406B (en) Compositions and methods for ophthalmic and/or other applications
HK40039406A (en) Compositions and methods for ophthalmic and/or other applications
Capítulo Nanoparticles as ocular drug delivery systems
HK40039407A (en) Compositions and methods for ophthalmic and/or other applications
AU2019204106A1 (en) Intraocular drug delivery device and associated methods
HK1226949B (zh) 用於眼科应用和/或其它应用的组合物以及方法
HK1226949A1 (en) Compositions and methods for ophthalmic and/or other applications

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4